PSA test in mid-life predicts long-term risk of prostate cancer
The results of a single total prostate-specific antigen test, done between the ages of 44 and 50, can reliably predict prostate cancer up to 25 years later, new research shows.
Dr. Hans Lilja, from Memorial Sloan-Kettering Cancer Center in New York, and colleagues analyzed the long-term predictive power of total PSA, free PSA, and human kallikrein 2 levels measured between the ages of 44 and 50 years in 21,277 men enrolled in the Malmo (Sweden) Preventive Project between 1974 and 1986. The analysis focused on the 498 patients who developed prostate cancer during follow-up through 1999, and on 1222 matched control patients who did not.
The results of a single total prostate-specific antigen test, done between the ages of 44 and 50, can reliably predict prostate cancer up to 25 years later, new research shows.
Dr. Hans Lilja, from Memorial Sloan-Kettering Cancer Center in New York, and colleagues analyzed the long-term predictive power of total PSA, free PSA, and human kallikrein 2 levels measured between the ages of 44 and 50 years in 21,277 men enrolled in the Malmo (Sweden) Preventive Project between 1974 and 1986. The analysis focused on the 498 patients who developed prostate cancer during follow-up through 1999, and on 1222 matched control patients who did not.